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Abstract 
Gelatin has many merits that encourage its use in the pulmonary delivery of anticancer drugs. It is 
a biodegradable denatured protein which possesses several functional groups that could be 
modified. Additionally, it has a balanced hydrophilic and hydrophobic characters, which facilitate 
the loading of chemotherapeutic agents. Accordingly, the purpose of the current work was to 
exploit this valuable biomaterial in the efficient pulmonary delivery of methotrexate in case of 
lung cancer. Gelatin nanoparticles were prepared via a desolvation method and the fabrication 
process was optimized using Box Behnken design of experiment. A comparative study on uptake 
of gelatin nanoparticles by lung adenocarcinoma cells and macrophages was implemented using 
flow cytometry. Investigation of the effect of different methotrexate loading techniques: 
encapsulation, post loading and chemical conjugation on the nanoparticles characteristics and 
cellular cytotoxicity was performed. Nano-in-microparticles were prepared by co-spray drying 
optimized nanoparticles with leucine. Results showed that Box Behnken design was able to 
optimize preparation parameters to yield uniform nanoparticles with suitable particle size for 
cancer cells uptake. The prepared nanoparticles demonstrated a preferential uptake by lung cancer 
cells. Additionally, methotrexate loaded nanoparticles demonstrated up to four fold significant 
reduction in methotrexate IC50. The spray dried gelatin nano-in microparticles demonstrated good 
aerosolization properties enabling lung deposition in the respirable airways. Thus, providing a 
promising platform for lung cancer therapy.  
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1. Introduction:
Lung cancer is by far the leading cause of cancer death among both men and women where  it
accounts for about 1.59 million deaths globally per year (Novello et al., 2016). Radiotherapy, 
surgery, chemotherapy or their combinations were the primary therapies for the disease (Mangal 
et al., 2017). However, conventional intravenous chemotherapy suffer from several drawbacks of 
such as poor distribution to the lungs accompanied with resistance and metastasis of the cancer 
cells. Therefore new treatment strategies with improved safety and efficacy such as the pulmonary 
delivery of nanoparticulate systems are in great demand. It aims at increasing the cytotoxic dose 
of drugs that could reach tumor cells to improve responses while minimizing systemic toxicity. 
Additionally, nanoparticulate systems could increase the residence time of chemotherapeutic agent 
in the lungs accompanied by a prolonged drug release with enhanced cellular internalization (Gill 
et al., 2011; Taratula et al., 2011; Jyoti et al., 2015).  
        Gelatin is a natural abundant biomaterial exhibiting unique and promising properties for 
delivery via the pulmonary route. It is obtained by the partial acid and alkaline hydrolysis of animal 
collagen to yield, respectively, type A with iso-electric point and type B with iso-electric point 
(Mohanty et al., 2005). Considered as a GRAS (Generally Regarded as Safe) material by the FDA 
and has been widely used in pharmaceuticals, cosmetics, as well as food products (Mohanty et al., 
2005). Gelatin is a polyampholyte having both cationic and anionic groups together with 
hydrophobic properties in approximate ratio of 1:1:1 that could enhance its ability to load both 
hydrophilic and hydrophobic drugs (Elzoghby, 2013). Moreover, its functional groups are 
accessible and can be easily chemically modified, a property which may be useful in developing 
targeted drug delivery vehicles (Busch, 2003). Gelatin is a denatured protein that could be readily 
degraded by collagenase enzymes. Additionally, in contrast to collagen, it exhibits low antigenicity 
(Elzoghby et al., 2012; Elzoghby, 2013; Hathout and Omran, 2016). Overall, its biodegradability, 
biocompatibility, chemical modification potential and cross-linking possibility make gelatin-based 
nanoparticles (GNPs) a promising carrier system for drug delivery. 
       Box Behnken (BBD), is a statistical design of experiment (DoE) which utilizes response 
surface methodology for the screening and optimization of critical factors in the fabrication of 
particulate systems. In contrast to traditional one factor at a time experiments (OFAT), DoE offers 
many advantages as: investigation of several factors at a time, reduction in total number of required 
experiments and detection of interaction between the investigated process variables (Zhang and 
Youan, 2010). Additionally, in order to investigate the effect of formulation variables on responses 
(dependent variables), BBD exclude simultaneous implementation of variables at their maximum 
or minimum levels, thereby the design points are selected as middle value for one factor and 
maximum or minimum for the other factors. By avoiding corners in the design space, BBD 
provides safety in its experiments setting (Marasini et al., 2013). Accordingly, DoE could 
contribute to enhanced quality attributes of the final product and cost and time reduction of the 
formulation process (Zhang and Youan, 2010; Marasini et al., 2013; Abdel-Hafez et al., 2014). 
      Methotrexate (MTX),  structure shown in Fig. 1 (Jouyban et al., 2011), is an antimetabolite of 
folic acid that can inhibit di-hydrofolate reductase enzyme and hence cellular proliferation. MTX 
influx into the cells is mediated by a reduced folate carrier and /or a proton coupled folate 
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transporter (Inoue and Yuasa, 2014). It has been used clinically for treatment of many neoplastic 
disorders and autoimmune diseases such as psoriasis and rheumatoid arthritis (Genestier et al., 
2000; Padmanabhan et al., 2009). However, the low tumor accumulation resulting from 
conventional MTX therapy leads to inefficient treatment, high risk for cancer resistance with a 
constant need for elevated doses. This is usually opposed by its severe side effects such as 
myelosuppression, lung distress, nephrotoxicity and ulcerative colitis. Therefore, many passively 
and actively targeted nanoparticulate carriers viz gold, carbon and PLGA nanoparticles (NPs) were 
proposed to overcome these limitations (Seo et al., 2009; Luo et al., 2014; Afshari et al., 2014; 
Ajmal et al., 2015).  
       Despite the great advantages presented by nanoparticulate systems for passive targeted cancer 
therapy, yet, their mass median aerodynamic diameter (MMAD) is not suitable for pulmonary 
delivery and they are mostly subjected to exhalation (Yang et al., 2008). Lung deposition is a 
particle size dependent process where Nano in Microparticles (NIM) with MMAD between 1-5 
µm could achieve deposition in the respirable airways (Kunda et al., 2015a; Kunda et al., 2015b). 
Therefore loading of NPs into a proper pulmonary delivery device should be implemented to 
enhance its lung deposition efficiency. Dry powder inhaler (DPI) presents many advantages such 
as; ease of drug administration, independence of actuation-inspiration coordination and enhanced 
formulation stability. Hence, NPs were incorporated into microparticles using soluble carrier e.g. 
lactose, leucine and trehalose (Bosquillon et al., 2001; Alfagih et al., 2015). NIMs could be 
prepared using spray drying, freeze drying, spray-freeze drying and super critical fluid 
technologies (Kunda et al., 2015c; Al-fagih et al., 2011).  
      In the current work, safe, biodegradable and low-antigenic nanoparticulate gelatin carriers, 
were designed, characterized and evaluated for their ability to deliver methotrexate. Optimization 
of the fabrication process was implemented to enhance NPs uptake to the lungs and subsequently 
cytotoxic effect. Effect of different loading techniques was investigated on drug loading and 
particles characteristics. Loading of NPs into suitable pulmonary delivery system were 
implemented to target the lung cancerous sites eliciting a significant cytotoxic response.  
2. Materials and methods:
2.1. Materials 
     Gelatin type A from porcine skin (Bloom 300), glutaraldehyde solution, glycine, leucine, 
methotrexate, Phorbol 12-myristate 13-acetate (PMA),N-Ethyl-N′-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC), (2-Aminoethyl)tri-methylammoniumchloride hydrochloride, 
trypsin from bovine pancreas, Roswell Park Memorial Institute medium (RPMI), Dulbecco's 
Modified Eagle's medium (DMEM) and fluorescein 5-isothiocyanate (FITC) were all purchased 
from Sigma Aldrich (St. Louis, MO, USA). Acetone of the analytical grade was obtained from 
Thermofisher (Massachusetts, US). Uranyl acetate was purchased from Agar Scientific (UK). 
A549 a human lung adenocarcinoma cell line and THP-1 a human monocytic cell line were 
purchased from American type culture collection ATCC (Manassas, US). 
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2.2. Methods 
2.2.1. Preparation of gelatin nanoparticles (GNPs) 
     GNPs were fabricated according to the previously described double desolvation technique 
(Coester et al., 2000; Azarmi et al., 2006). Briefly, 1.25 g of gelatin were dissolved in 25 mL of 
de-ionized water at 40ºC, and 25 mL of acetone were added to precipitate the high molecular 
weight fraction (HMwt) of gelatin. The supernatant was discarded and the precipitate was re-
dissolved in water under constant heating at 40ºC. The pH of the solution was adjusted to 2.5 with 
5M HCl. Following on, gelatin solution was secondarily desolvated by dropwise addition of 75 
mL of acetone and cross-linking of the prepared NPs was aided using glutaraldehyde solution 
(25%v/v) under magnetic stirring. Glycine solution (751mg/100ml) was added and stirred at 500 
rpm for 1 hour to block the residual aldehyde groups (CHO) of glutaraldehyde and thereby 
stopping its action. Finally, acetone was removed utilizing a rotary vacuum evaporator and NPs 
were purified by three fold centrifugation at 30000 rpm, 40 min and 4ºC (Optima XPN 
ultracentrifuge, Beckman Coulter, USA) and re-dispersed in de-ionized water. The resulting GNPs 
were stored at 4ºC for further applications. 
2.2.2. Optimizing the prepared gelatin nanoparticles using Box Behnken 
experimental design 
     Optimization of GNPs preparation process was implemented using the response surface 
methodology; specifically BBD in order to yield NPs with suitable uniform particle size (PS). 
Effect of  stirring rate, cross-linker solution volume, cross-linking time were studied where three 
levels for each factor with triplicate center points were selected to create the model, Table 1. 
Experiments setting and data analysis were performed using Design Expert® v.7.0 (Design Expert® 
Software, Stat Ease®, MN). The model was evaluated using one-way analysis of variance 
(ANOVA), lack of fit and regression analysis.  
2.2.3. Preparation of FITC labeled GNPs 
        FITC conjugated NPs were fabricated according to a previously described method (T.H.The 
and T.E.W.Feltkamp, 1970). Briefly, the pH of NPs dispersion in de-ionized water was adjusted 
to 9.5 using carbonate buffer, 20 µL from (5mg/mL) FITC solution in DMSO was added to GNPs 
which were then left under magnetic stirring for 4 h at room temperature. Unbound FITC 
molecules were removed by threefold centrifugation at 30000 rpm, 4ºC for 40 min (Optima XPN 
ultracentrifuge, Beckman Coulter, USA) followed by re-dispersion in de-ionized water. 
2.2.4. Methotrexate loading 
     Loading of methotrexate (MTX) was performed on the optimized formulation. The loading 
process was implemented using three different methods: encapsulation, post loading on cationized 
GNPs and chemical conjugation in order to evaluate effect of the loading technique on the physical 
properties and entrapment efficiency of the prepared gelatin NPs. 
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2.2.4.1. Methotrexate loading using the encapsulation technique 
     The steps of GNPs preparation were performed as previously stated in section 2.2.1. with drug 
addition before the second desolvation step where 10 mg of MTX were added to gelatin solution 
then the amount of acetone was added dropwise. This was followed by addition of glutaraldehyde 
solution to crosslink the prepared NPs (Bharti et al., 2014). 
2.2.4.2. Methotrexate loading using the post-loading technique 
     Initially, GNPs were cationized according to a previously reported cationization protocol 
(Zwiorek et al., 2005; Azarmi et al., 2006; Zwiorek et al., 2008), through activation of the free 
carboxylic groups of gelatin on particles surface to be chemically conjugated with a polyamine 
compound. Briefly, the pH of GNPs dispersion was adjusted to 4.5 utilizing 0.1 M NaOH and 
stirred with a molar excess of cholamine hydrochloride for 30 min. An amount of 30 mg of EDC 
was added and the dispersion was kept under constant stirring overnight. Purification of the NPs 
was achieved by centrifugation (30000 rpm, 40 min and 4ºC) and the pellet was re-dispersed in 
de-ionized water with the process repeated three times.  
     Thereafter, 15 mg of cationized NPs were centrifuged and re-suspended in a vial containing 
(0.125, 0.25, 0.5, 1 and 2 mg/mL) MTX in phosphate buffer solution (PBS) of pH 8 and was left 
rotating for 1 h at 100 rpm on a Hula mixer (Life Technologies, Invitrogen, UK). Based on the 
loading results, selected concentration of MTX was then investigated at the respective time points 
(2, 3, 4 h). Drug loading in each case was analyzed using HPLC as will be explained later and 
optimum post loading conditions were adopted for further investigations. 
2.2.4.3. Methotrexate loading using the chemical conjugation technique 
     The method was adopted through activation of MTX carboxylic groups to attack free amino 
groups on NPs surface. Hence, 30mg of EDC were stirred with 10 mg of MTX in PBS (pH 8) for 
30 min. then, 60 mg of GNPs were added and left overnight under magnetic stirring (Shin et al., 
2014).Validation of MTX chemical conjugation was carried out using proton NMR spectroscopy 
using Bruker avance III 600 MHz spectrometer with topspin 3.5 software (Bruker, Massachusetts, 
USA). 
2.2.5. Characterization of fabricated nanoparticles 
2.2.5.1. Determination of the particles yield 
     To calculate the yield of the optimized formula of GNPs, the HMwt fraction initially 
precipitated following the first desolvation step was freeze dried for 2 days and weighed. The 
resultant dispersion of GNPs was also freeze-dried (Heto FD2.5, Heto-Holten, Denmark) over 2 
days at -60 ºC, 0.065 mbar and then weighed. The yield was calculated for the optimized 
formulation according to equation (1): 
𝑌𝑖𝑒𝑙𝑑(%) =
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑓𝑟𝑒𝑒𝑧𝑒 𝑑𝑟𝑖𝑒𝑑 𝑁𝑃𝑠
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑡ℎ𝑒 𝐻𝑀𝑤𝑡 𝑔𝑒𝑙𝑎𝑡𝑖𝑛 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 
 𝑥 100  Equation (1) 
2.2.5.2. Particle size, PDI and zeta potential 
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      Mean particle size (PS), polydispersity index (PDI) and zeta potential (ζ ) measurement were 
carried out for the prepared NPs using dynamic light scattering (DLS)  technique for PS and PDI 
and laser Doppler velocimetry for ζ (Zetasizer, Malvern, UK). All measurements were carried out 
in triplicates, means and standard deviations (SD) were also calculated. The effect of pH on ζ of 
GNPS and cationized GNPs was determined also by laser Doppler velocimetry. For the 
measurement, pH of the NPs dispersion was adjusted to values between 2.5 and 10 using 0.25 N 
HCl or 0.25 N NaOH.  
2.2.5.3. Determination of drug loading 
      The drug content in the prepared GNPs was determined indirectly by analyzing the amount of 
free drug remaining in the supernatant after centrifugation of the loaded NPs according to a 
previously described high performance liquid chromatography (HPLC) validated method (Oliveira 
et al., 2015). Briefly, an HPLC instrument equipped with UV-visible detector was set to 303 nm. 
Hypersil BDS C18 column and a mobile phase consisting of methanol and ammonium acetate 
buffer (pH 6) with a ratio of (25:75) were selected for the separation technique. At 25ºC, an 
isocratic elution was utilized with a flow rate of 1mL/min. MTX loading was calculated using 
equation (2): 
𝐷𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 (
µ𝑔
𝑚𝑔 𝑜𝑓 𝑁𝑃𝑠
) =  
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑑𝑟𝑢𝑔 𝑎𝑚𝑜𝑢𝑛𝑡−𝑟𝑒𝑚𝑎𝑖𝑛𝑖𝑛𝑔 𝑑𝑟𝑢𝑔 𝑎𝑚𝑜𝑢𝑛𝑡
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑔𝑒𝑙𝑎𝑡𝑖𝑛
 Equation (2) 
2.2.5.4. In-vitro drug release 
       MTX loaded NPs dispersion equivalent to 20 mg of NPs were mounted into dialysis bags 
(MWCO 3500 D) and dialyzed against 50 mL of PBS (pH 7.4) for 72 h. NPs dispersion and dialysis 
media were kept under continuous magnetic stirring at 37 ºC. Samples were withdrawn at fixed 
time intervals and were replaced with fresh PBS. Investigation of the release in the presence of a 
proteolytic enzyme was also accomplished. Therefore, the NPs were accompanied by 10 mg of 
trypsin in the dialysis bag. Samples were analyzed for the amount released of MTX utilizing HPLC 
as previously described in section 2.2.5.3. For evaluation of the release kinetics, the obtained 
release data were fitted into the Korsmeyer-Peppas exponential equation (3) in order to determine 
the mechanism of drug release 
𝑄 = 𝐾𝑡𝑛    Equation (3) 
Where 𝑄 is the percentage of drug released at time 𝑡 and 𝑘 is a constant incorporating the structural 
and geometric characteristics of the investigated dosage form. The diffusional exponent 𝑛 is an 
indicator of the mechanism of drug transport from the dosage form. A value of 𝑛 ≤ 0.5 indicates 
that drug release is controlled by Fickian diffusion, whereas a value of 0.5 ˃ 𝑛 ˃1 the release is 
described as anomalous, implying that a combination of diffusion and erosion contributes to the 
control of drug release (Costa and Lobo, 2001). 
2.2.5.5. Flow cytometry experiment 
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      A comparative uptake of FITC–labeled GNPs into lung adenocarcinoma (A549) cells and 
macrophages (THP-1) were evaluated using flow activated cell sorting (FACs). THP-1 human 
monocyte cells were differentiated into macrophages using PMA as follow: the cells were seeded 
into 6 well plates at a density of 1×106 cells per well, and were then incubated in RPMI medium 
containing 50 ng/mL PMA for 48 h. Unattached cells were removed and washed with PBS three 
times (Takashiba et al., 1999; Park et al., 2007). A549 human lung adenocarcinomic cells were 
plated at density of 1×106 cells per well into a 6 well culture plate and were maintained in DMEM 
medium.  
     Macrophages and lung adenocarcinomic cells were treated each with 4 mg of FITC labeled 
GNPs suspended in 3mL of RPMI and DMEM media, respectively. After 4 h of incubation at 
37ºC, the treated cells were washed three times with phosphate buffer saline (pH 7.4), trypsinized 
and re-suspended in fresh media. Flow cytometric analysis was performed using a flow cytometer 
(BD AccuriTM C6 flow cytometer, BD Biosciences, US). The data were analyzed using BD Accuri 
C6 software by gating on live cell population with a minimum of 10000 events were recorded. 
Median FLA-1 was chosen for comparative fluorescence changes. Median FLA-1 was compared 
in macrophages and A549 cells before and after treatment with FITC- labeled GNPs. 
 2.2.5. 6. In-vitro cytotoxicity assay 
     Cell viability was investigated using MTT assay. A549 cells were seeded into 96 well plates at 
a density of 1×104 cell per well in DMEM media supplemented with 10% Fetal serum protein, 100 
IU/mL penicillin and 100 mg/mL streptomycin. They were incubated at 37ºC in an atmosphere of 
5% CO2 for 24 h. Cells were then treated with serial concentrations of MTX loaded GNPs, blank 
GNPs, cationized GNPs and free MTX solution in PBS (pH 7.4). Additionally, 10% DMSO and 
fresh medium were utilized as positive and negative controls, respectively. Following 24 h of 
incubation, the cells were washed with phosphate buffer saline and 100 µL of fresh medium and 
20 µL of MTT solution (5mg/mL MTT) were added. After 4 h of incubation, the formed formazan 
crystals were dissolved with 100 µL DMSO. Absorbance in each well was measured by Clariostar 
plate reader (BMG Labtech, Germany) at 570 nm (Osman et al., 2013; Afshari et al., 2014). % 
Cell viability was calculated according to the following equation: 
% 𝑐𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑎𝑓𝑡𝑒𝑟 24 ℎ 𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑖𝑜𝑛 =
 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙 𝑤𝑖𝑡ℎ 𝐺𝑁𝑃𝑠  × 100
𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒𝑜𝑓 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙 (𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
 Equation (4)  
2.2.6. Preparation of spray dried nano-in microparticles (NIM)  
     Freshly prepared optimized MTX loaded NPs were spray dried using leucine as carrier at a ratio 
of 1:1.5, respectively. Büchi B-290 mini spray-dryer (Büchi Labortechnik, Flawil, Switzerland) 
was used at a pump capacity of 20% and an atomizing air flow of 414 L/h. The dry particles were 
separated from the air stream using a high-performance cyclone (Büchi Labortechnik, Flawil, 
Switzerland) where they were collected and stored in a desiccator until further use. Preparation of 
spray dried NIM was implemented at variable conditions of temperature (75-100-125ºC), 
aspiration rate (50-75-100%) and feed concentration (4-8-12mg/mL) after proper dilution with 
water in order to optimize the yield and residual moisture in the spray dried NIM using BBD. 
Supplementary material Table 2 shows the formulae prepared for this optimization study.  
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2.2.7. Characterization of spray dried NIM 
2.2.7.1. Spray dried powder yield 
       The percentage yield of dry powder was calculated according to equation (5): 
𝑌𝑖𝑒𝑙𝑑 (%)  =  
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑝𝑜𝑤𝑑𝑒𝑟 𝑐𝑜𝑙𝑙𝑒𝑐𝑡𝑒𝑑 𝑎𝑓𝑡𝑒𝑟 𝑠𝑝𝑟𝑎𝑦 𝑑𝑟𝑦𝑖𝑛𝑔
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑑𝑟𝑦 𝑚𝑎𝑠𝑠 𝑢𝑠𝑒𝑑 𝑓𝑜𝑟 𝑡ℎ𝑒 𝑝𝑟𝑒𝑝𝑎𝑟𝑎𝑡𝑖𝑜𝑛
𝑥100               quation (5) 
2.2.7.2. Moisture content determination 
       The moisture content of the spray dried NIM was evaluated using thermo-gravimetric analysis 
(TGA Q50, UK equipped with TA universal 2000 software). Briefly, 10 mg of the powder were 
heated between 25 and 350ºC at a rate of 15 ºC per min. Data analysis for residual moisture were 
investigated between 25 to 120ºC. 
2.2.7.3. Particles morphology 
      Spray dried powders were visualized using scanning electron microscopy (SEM) (FEI 
Quanta™ 200 ESEM, Holland). Samples were mounted on aluminium stubs (pin stubs, 13 mm) 
layered with a sticky conductive carbon tab and coated with palladium (10–15 nm) using a sputter 
coater (EmiTech K 550X Gold Sputter Coater, 25 mA). 
2.2.7.4. Nanoparticles recovery 
     To ensure the recovery of NPs from spray dried powder with suitable PS for cellular uptake, an 
aliquot of 5 mg of spray dried powder was dispersed into 2 mL of deionized water. PS, PDI and ζ 
were measured for the released NPs. Moreover, the particles were stained with uranyl acetate and 
visualized using transmission electron microscopy (TEM), electron micrographs were recorded 
using a MegaView3 CCD camera and AnalySIS software (EMSISGmbh, Germany) in a FEI 
Tecnai G2 spirit BioTWIN electron microscope.  
2.2.7.5. In-vitro aerosolization studies 
      Aerosolization performance of spray dried gelatin NIM was assessed using the next generation 
impactor (NGI). An accurately weighed amount (20 mg) of spray dried gelatin NIM were filled 
into each hydroxypropyl methylcellulose capsule (size 3), 10 capsules were used for each run and 
the experiment was performed in triplicate. Capsules were punctuated with Cyclohaler and 
aerosolized into the NGI (Copley scientific pump, Nottingham, UK) at a flow rate of 60 L/min for 
4 seconds. NGI plates were coated with 1% glycerol in acetone to prevent bouncing of fine 
powders between plates (Tawfeek et al., 2013). The plates were weighted before and after 
aerosolization of the powders (Sham et al., 2004). Mass median aerodynamic diameter (MMAD) 
was calculated using log probability analysis. Respirable fraction is the fraction of emitted dose 
deposited in the NGI with dae<4.46 μm. Emitted and respirable fraction were calculated according 
to the following equations:  
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𝐸𝑚𝑖𝑡𝑡𝑒𝑑 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 (𝐸𝐹%) =
𝑀𝑓𝑢𝑙𝑙−𝑀𝑒𝑚𝑝𝑡𝑦
𝑀𝑝𝑜𝑤𝑑𝑒𝑟
× 100        Equation (6) 
Where Mfull and Mempty are the masses of the capsules before and after aerosolization, respectively. 
Mpowder  is the mass of the powder. 
𝑅𝑒𝑠𝑝𝑖𝑟𝑎𝑏𝑙𝑒 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 (𝑅𝐹%) =
𝐹𝑃𝐷
𝐸𝐷
 × 100             Equation (7) 
Where fine particle dose (FPD) is the total weights of powder deposited from plate number 2 to 
plate number 7. Emitted dose (ED) could be calculated as the difference between the mass of the 
capsule before and after aerosolization  𝑀𝑓𝑢𝑙𝑙 − 𝑀𝑒𝑚𝑝𝑡𝑦. 
2.2.8. Statistical analysis 
       All data are reported as mean of 3 determinations ± standard deviation (SD). Experiments 
setting and data analysis for GNPs and spray dried NIM optimization were performed using Design 
Expert® v.7.0 (Design Expert® Software, Stat Ease®, MN). Other data obtained were analysed 
statistically by one-way ANOVA and two-way ANOVA was utilized for statistical analysis of NPs 
uptake data. Statistical significant difference was noted when p ˂ 0.05.  
3. Results and discussion
3.1. Optimization of the prepared GNPs 
     In pulmonary delivery, cellular uptake of passively targeted nanoparticulate carriers is a size 
dependent process where NPs with mean PS between 100–200 nm could be preferably 
endocytosed by cancerous cells (Nagayasu et al., 1999; Kulkarni and Feng, 2013; Abozeid et al., 
2016). Accordingly, optimization of preparation conditions was implemented using BBD to yield 
NPs possessing PS suitable for lung cancerous cells endocytosis.  
    All the prepared formulations demonstrated a mean PS ranging from 180.31±10.10 to 469.56± 
7.37 nm as shown in Table 2. The obtained responses were fitted to a proper reduced quadratic 
model after elimination of the insignificant terms (p>0.05) from the model equation. The equation 
describing the resultant quadratic model was found to be: 
 𝑌 = 268.71 − 36.34  ∗  𝐴 − 36.9 ∗ 𝐵 − 30.44 ∗ 𝐶 + 60.83  ∗  𝐴 ∗  𝐵 + 58.24  ∗  𝐵2 −
23.35 ∗  𝐶2                                                                                               Equation (8) 
  Where Y is the PS, A is the cross-linking solution volume, B is the cross-linking reaction time, 
and C is the stirring speed. 
      The response surface reduced quadratic model was significant with respect to these model 
terms; A, B, C, AB, B2 and C2. Model reliability was verified utilizing ANOVA, lack of fit test 
and regression analysis. Regarding the ANOVA test, the obtained p-value was less than 0.05, 
actually scoring a value of 0.0001, see supplementary material Table 1. Moreover, the lack of fit 
test, demonstrating adequacy of the model to represent the variation of the generated responses, 
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depicted a p-value of 0.0790 indicating favorable “insignificant results” (Safwat et al., 2017; 
Naguib et al., 2017) supplementary material Table 1. In regression analysis as shown in 
supplementary material Table 1, the R2 and the adjusted R2 values indicate the variation of the 
results around the mean introduced by the model and their fitting to the reduced corrected model, 
respectively. Predicted R2 is a measure of how efficient the model predicts a new observation. The 
adjusted R2 and predicted R2 were within 0.2 of each other to be in a reasonable agreement. Finally, 
adequate precision is a measure of the experimental signal to noise ratio. The adequate precision 
scored 24.848, a value higher than the critical value of 4, indicating high signal to noise ratio and 
sufficiency of the model to navigate the experimental space (Zhang and Youan, 2010; Marasini et 
al., 2013; Abdel-Hafez et al., 2014). Consequently, the model could be utilized for GNPs size 
optimization and prediction. 
     Fig. 2 represents the contour and 3D plots of the model. It is obvious that increasing the cross-
linking solution volume and stirring speed were associated with a significant reduction in PS of 
the resulting NPs. This can be ascribed to glutaraldehyde that is essential for gelatin assembly into 
nanospheres, stability and hardening (Azarmi et al., 2006; Elzoghby, 2013). Moreover, the 
shearing force from higher stirring speeds helps in particles rounding and spheronization 
(Dinarvand et al., 2004; Jahanshahi et al., 2008). Additionally, a moderate cross-linking time was 
selected,  this can be justified by the fact that the increase in reaction time could enhance 
probability of interparticulate cross-linking (Wong et al., 2011). Hence, the optimized preparation 
conditions were: stirring speed of 1600rpm, cross linking time of 12 h and cross linking solution 
volume of 231 µL, (Table 2) which resulted in a formulation with mean PS of 180.31± 10.10nm, 
PDI of 0.05±0.03 and ζ of 18.50± 1.81 mV, which was selected for further investigations. 
Furthermore, a desirable yield of 84.18± 0.26 % from the HMwt gelatin fraction was obtained. 
 
3.2. Methotrexate loading 
      The effect of loading technique on the characteristics of MTX loaded NPs in terms of PS, PDI, 
ζ and MTX loading, is displayed in Table 3. It can be seen that a negligible loading was observed 
in the NPs prepared with encapsulation technique compared with other techniques. This may be 
explained due to MTX moderate solubility in acetone accompanied with long stirring time, which 
could enhance its leakage from the NPs during fabrication. 
     Concerning post loaded NPs, due to the polyampholytic nature of gelatin and MTX, the pH of 
their dispersion medium controls the charge they carry, consequently, the electrostatic attraction 
between NPs and the drug then the loading efficiency. As shown in Fig. 3A, cationization of gelatin 
was carried out in order to preserve its positive net charge during post loading at pH 8, as 
previously addressed by (Zwiorek et al., 2005). Whereas MTX will acquire a negative charge at 
this pH and could be electrostatically attracted to the NPs. Figure 3B demonstrates the effect of 
MTX concentration on the amount adsorbed per mg of NPs. Expectedly, a significant increase in 
loading was observed with higher concentrations at 1 hour as a higher amount of MTX was 
available for adsorption. Furthermore, Fig. 3C shows a maximum loading of MTX at 1 hour with 
no significant change in the loading with longer time periods (p˃0.05). This may be attributed to 
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saturation of the NPs to adsorption (Kunda et al., 2015). For MTX post loaded NPs preparation, 
cationized GNPs was stirred with 2mg/ML of MTX for 1h. Effective MTX adsorption to 
cationized NPs could be indicated by the reduction in ζ of the cationized NPs from 18.08±1.02 at 
pH 8 to 14.03±0.05 mV by the negatively charged adsorbed MTX (p˂0.05) (Shutava et al., 2009).  
       In another approach, MTX was chemically conjugated to NPs through amide bond formation 
that was assisted by EDC activation of MTX carboxylic group. In Fig. 4, the NMR charts depicts 
that the peaks at 6.8, 7.75 and 8.58 ppm of MTX were also present in the chemically conjugated 
gelatin and normally absent in gelatin (Fu et al., 2017) indicating that MTX was successfully 
conjugated. Moreover, the minimal PS reduction of the chemically conjugated NPs compared with 
blank gelatin NPs (p˂0.05) could be attributed to the longer stirring time that NPs were subjected 
to it, which may enhance particles rounding and spheronization. Based on the loading results NPs 
loaded by encapsulation were excluded from further studies.  
 
3.3. In-vitro drug release results 
     In fig. 5, drug release results from post loaded NPs reveal an initial burst release of 43.25 ±1.18 
% of MTX during the first 8 h that was followed by a sustained release with a slower rate for 24 
h, then no release was noticed until 72 h. On the other hand, a higher initial release of MTX (58.90 
± 4.1 %) and almost a complete drug release was observed after 36 h in the presence of trypsin. 
On the other hand, no release of MTX from the chemically conjugated NPs was observed in the 
absence of trypsin. In contrary upon its addition, where only 35.71 ± 3.66 % was released to the 
recipient compartment during 72 h. Enhancement of drug release from the prepared NPs in the 
presence of trypsin could be attributed to the proteolytic action of trypsin that degraded GNPs into 
small fragments causing MTX release (Abozeid et al., 2016). Degradation of GNPs occur either 
after endocytosis or by extracellular proteases. The Gly-X-Pro sequence (where X represents 
lysine, arginine, methionine and valine) that is responsible for the triple helical structure of gelatin, 
is initially attacked by collagenase enzyme which is followed by further degradation that is 
implemented by other enzymes like gelatinase and other non specific proteinases (Abozeid et al., 
2016). However, incomplete drug recovery from chemically conjugated NPs could be explained 
by, upon enzymatic degradation of NPs, only free MTX molecules and/or MTX- peptide fragments 
of molecular weight lower than 3500 daltons (cut off value of the dialysis membrane) could be 
released from the dialysis bag. Where only free MTX molecules could be analyzed in the release 
medium (Leo et al., 1999).  
     The release kinetics was evaluated by fitting the obtained data (during the first 24 h) into 
Korsmeyer-Peppas equation. Based on the results, MTX release from the post loaded NPs recorded 
an (n) exponent of 0.37 and R2 of 0.93, which suggest that a Fickian diffusion process is 
predominant. This could be attributed to the strong electrostatic attraction between the cationic 
GNPs and negatively charged MTX molecules which could control the drug diffusion to the 
surrounding medium (Shutava et al., 2009). MTX release from post loaded (n=0.69, R2=0.95) and 
chemically conjugated NPs (n=0.57, R2=0.96) in the presence of trypsin demonstrated an 
anomalous transport. This could be attributed to the erosion of gelatin matrix by the enzymatic 
degradation (Gao et al., 2013). It is worth mentioning that despite of the release mechanism of 
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MTX from the GNPs, the NPs were designed to be uptaken by the cancerous cells as demonstrated 
in the following section. The release profiles confirmed the ability of the NPs to hold the drug 
sufficiently until cellular uptake. 
3.4. Gelatin nanoparticles uptake 
     Lung macrophages are one of the major host defense mechanisms and a serious determinant 
for the fate of NPs delivery to the lungs. Therefore, to ensure optimum activity and cytotoxic 
efficiency of the prepared NPs, a comparative uptake of GNPs was evaluated between the 
macrophages and the lung adenocarcinoma cells by flow cytometry. Figure 6 and Table 4 illustrate 
the fluorescence changes reflected by median FLA-1 between cells treated with FITC- labeled NPs 
and control untreated cells, where median FLA-1 of A549 treated cells was significantly elevated 
compared to the macrophages counterpart (p˂0.05). This may be attributed to, the fact that 
phagocytosis is a PS dependent process where particles less than 260 nm tend to escape from 
phagocytic clearance (Yang et al., 2008) whereas FITC- labeled NPs had a mean PS of 188 ± 6.20 
nm as in Table 3. Additionally, cancerous cells shows a favorable uptake to NPs between 100–200 
nm  (Nagayasu et al., 1999; Kulkarni and Feng, 2013). This was correlated with the results obtained 
by Azarmi, (Azarmi et al., 2006), where three groups of GNPs with sizes of 190, 283 and 330 nm 
were investigated for their uptake into osteosarcoma cells. GNPs with size of 190 nm showed the 
highest uptake into osteosarcoma cell line. In addition, GNPs prepared with PS of 260 or higher 
demonstrated significant uptake into macrophage cells (Coester et al., 2000; Coester et al., 2006). 
3.5. Cytotoxicity assay 
      MTT assay was utilized to investigate toxicity profiles of MTX loaded NPs on the 
adenocarcinomic A549 cell lines. Both blank gelatin and cationized NPs were well tolerated by 
the cells up to concentration of 2 mg/mL showing cell viabilities of 85 ± 2.61% and 80 ± 1.5 %, 
respectively as previously reported by (Metwally et al., 2016). Furthermore, Fig. 7 demonstrates 
that post loading and chemical conjugation of MTX to gelatin NPs could effectively enhance its 
cytotoxic activity and reduce its IC50 by two and four folds, respectively. The enhanced activity of 
the post loaded NPs compared to free MTX could be explained by the higher amounts of MTX 
that could be delivered by NPs to the cells. Consequently, a greater cytotoxic effect and lower IC50 
values were observed (Afshari et al., 2014). Chemically conjugated NPs showed lower IC50 
compared to post loaded NPs, this could be attributed to smaller PS of chemically conjugated NPs 
which may promote their uptake by the A549 cells (Nagayasu et al., 1999; Kulkarni and Feng, 
2013). In addition, MTX is an analogue to folic acid which may promote NPs targeting and 
receptor mediated endocytosis to over expressed folate receptors in cancerous cells (Luo et al., 
2014). Therefore, MTX chemically conjugated NPs were selected for spray drying and DPI 
preparation. 
3.6. Preparation of spray dried NIM 
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      As prevoiusly disscussed, despite the many advantages addressed by the NPs when utilized for 
lung cancer treatment, however large fraction of NPs could be exhaled easily due to its MMAD is 
not suitable for the pulmonary delivery. Therefore, spray drying of the optimized formula with 
leucine was adopted to enhance its delivery to lower respiratory tract regions via DPI.  
    Based on the applied process variables, the yield and moisture content varied from 19.0 ±5.90 
to 84.50±6.80% and from 0.56±0.05 to 1.32±0.50%, respectively, see Table 2 supplementary 
material. The results of  data analysis according to the BBD  are shown in Table 3 supplemntary 
material. The design analysis revealed that the yield increased with increasing the 3 investigated 
factors while the moisture content decreased with increasing temperature and feed concentration. 
The 3D contour plots of the effects of the various variables are presented in Fig. 1 supplementary 
material. Accordingly, the following conditions were selected: inlet temperature of 125 ºC, 
aspirator capacity of 100 % and a feed concenteration of 8 mg/mL. Hence, a desirable yield of 
84.50 ± 6.80 (%) was obtained. Moreover, the low moisture content 0.98 ± 0.28 (%) reported from 
the TGA thermogram presents a good drying efficiency therefore the dry powder formulations are 
likely to show good storage stability and dispersibility. 
3.7. Characterization of spray dried NIM 
3.7.1. Particles morphology 
      SEM of spray dried GNPs, Fig. 8 A&B show irregular particles possessing a notch in its center 
and a rough outer surface. This doughnut shape could be attributed to the accelerated rate of 
evaporation due to the high inlet temperature that led to trapping of excessive amounts of vapour 
inside the particle (Yang et al., 2015). 
3.7.2. Recovery results of the nanoparticles 
      The released NPs from spray dried powder, had a mean PS of 160 ± 9.78 nm, PDI of 0.183 ± 
0.004 and  ζ of -23 ± 0.15 mV that were insignificantly different from those obtained for the MTX 
chemically conjugated NPs before spray drying at (p˃0.05). Furthermore, as demonstrated from 
the TEM in Fig. 8 C&D, there was no visual difference in shape of the NPs before and after re-
dispersion from spray dried powder. Accordingly, spray drying conditions were able to preserve 
NPs characteristics and consequently their cellular uptake. 
3.7.3. In-vitro aerosolization studies 
     Powder deposition results presented a powder recovery from the cyclohaler of 96.08 ± 0.38 
(%), MMAD of 2.59 ± 0.31 µm and a respirable fraction of 49.53 ± 2.10 (%), suggesting a lung 
deposition in the respirable airways. This has been ascribed to the hydrophobic alkyl chain of 
leucine as a carrier which could reduce the microparticles cohesive interparticulate interactions 
and surface energy (Tawfeek et al., 2011). In addition, the particles rough surface that resulted in 
particles with minimal sites for interparticulate crosslinking, hence it demonstrated enhanced 
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dispersibility during aerosolization (Tawfeek et al., 2011). Moreover, the lower residual moisture 
in spray dried particles which could be favorable for particles flowability (Tawfeek et al., 2011). 
Similar reports have also demonstrated the enhanced aerosol performance with leucine containing 
formulations (Najafabadi et al., 2004; Feng et al., 2011; Sou et al., 2013). 
 
4. Conclusion  
      Optimization of GNPs preparation parameters could be implemented with Box Behnken 
design, to yield NPs with suitable particle size for lung cancer cells uptake and cytotoxic 
efficiency. Moreover, an enhanced uptake of the gelatin NPs by the lung adenocarcinoma cells 
compared to macrophages was confirmed which could facilitate the chemotherapeutic agents’ 
delivery to the cancerous tissues. Consequently, investigation of different techniques in loading of 
MTX and cytotoxicity assays of the resultant formulations were carried out. The chemical 
conjugation of MTX to gelatin NPs could successfully augment the cytotoxic activity of MTX 
compared to the free drug and the NPs prepared using other techniques. Finally, spray drying of 
MTX chemically conjugated NPs showed good aerosolization properties and lung deposition in 
the broncho- alveolar airways.  
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Table 1. Process parameters used in the Box Behnken design for optimizing GNPs fabrication 
conditions. 
Parameter Unit 1 2 3 
Stirring speed rpm 800 1200 1600 
Crosslinking time Hour 8 12 16 
Crosslinking 
solution volume 
µL 99 165 231 
Table 2. Structure of Box-Behnken design with the corresponding experimentally determined 
particle size results of the prepared GNPs. 
Run Stirring speed 
(rpm) 
Crosslinking 
time (h) 
Crosslinking 
solution volume 
(µL) 
Particle size 
(nm) 
1 1 2 1 282.33 ± 3.95 
2 1 2 3 247.20 ± 4.59 
3 3 2 3 180.31 ± 10.10 
4 1 1 2 373.36 ± 7.04 
5 2 1 1 469.56 ± 7.37 
6 3 1 2 299.91 ± 13.45 
7 2 2 2 262.83 ± 4.55 
8 1 3 2 316.73 ± 3.13 
9 3 3 2 224.20 ± 5.54 
10 2 1 3 265.83 ± 6.10 
11 2 3 1 266.46 ± 6.31 
12 3 2 1 271.73 ± 8.33 
13 2 3 3 306.06 ± 6.91 
14 2 2 2 273.70 ± 7.75 
15 2 2 2 269.43 ± 3.28 
 Results are expressed as (Mean ± SD, n=3) 
Table 3. Characteristics of fabricated gelatin NPs. 
Formulas Size (nm) PDI Zeta potential  
(mV) 
Drug loading 
(µg/mg) 
Plain NPs 180.31 ± 10.10 0.05 ± 0.030 18.50 ± 1.81 
Cationized plain 
NPs (pH 8) 
FITC-  
labelled NPs 
Encapsulated 
MTX NPs 
217.78 ± 23.92 
188.00 ± 6.20 
303.38 ± 3.30 
0.08 ± 0.047 
0.07 ± 0.003 
0.14 ± 0.008 
18.08 ± 1.02 
-20.00 ± 1.20
17.21 ± 0.17 4.10 ± 0.39 
Post Loaded 
MTX NPs 
255.70 ± 5.92 0.14 ± 0.010 14.03 ± 0.05 96.00 ± 3.41 
Chemically 
Conjugated 
MTX NPs 
148.45 ± 2.49 0.05 ± 0.020 -22.56 ± 0.43 84.60 ± 0.23 
Results are expressed as (Mean ± SD, n=3). 
Table 4. Median FLA-1 values for control and treated cells with FITC – labelled gelatin NPs. 
Cells Control cells Treated cells 
A549 7180 ± 20 1,709,633 ± 1080 
Macrophages 2408 ± 60 40385 ± 154 
Control cells are untreated cells with FITC-NPs, results are expressed as (Mean ± SD, n=3). 
Figure Titles 
Fig. 1.  Chemical structure of methotrexate.  
Fig. 2. Contour plots (right panels) and 3D surfaces (left panels) generated by Box- Behnken 
design representing the effect of a-glutaraldehyde volume (GA), b-crosslinking time at 
different stirring speed at: 800 rpm (Upper panels), 1200 rpm (Middle panels) and 1600 rpm 
(Lower panels) on the particle size of the fabricated gelatin nanoparticles. Particle size 
decreases from red to blue color. 
Fig. 3. (A) Effect of pH on the zeta potential of gelatin NPs and cationized gelatin NPs. (B) 
Effect of MTX concentration and (C) stirring time on the loading of MTX on cationized 
gelatin nanoparticles (Mean ± SD, n=3). 
Fig. 4. H-NMR spectra for MTX and chemically conjugated MTX. All were dissolved in 
D2O. 
Fig. 5. In-vitro release profiles for MTX post loaded NPs and MTX chemically conjugated 
NPs in absence and presence of trypsin in phosphate buffer pH 7.4 (Mean ± SD, n=3). 
Fig. 6. The fluorescence changes of the cells before and after treatment with FITC-labelled 
GNPs indicating the enhanced uptake into the A549 cells compared to the macrophage cells. 
(A) macrophage cells, (B) macrophage cells treated with FITC-labelled GNPs, (C) A549
cells, (D) A549 cells treated with FITC-labelled GNPs.
Fig. 7. In-vitro cytotoxicity profiles for MTX, post loaded and chemically conjugated 
nanoparticles. (Mean ± SD, n=3). 
Fig. 8. SEM micrographs of MTX chemically conjugated GNPs/NCMPs (A) and (B) (scale 
bar 20 & 5 µm respectively), TEM images of  MTX chemically conjugated GNPs (C) before 
and (D) after re-dispersion from spray dried GNPs/NCMPs (scale bar 200 nm). 










Supplementary material 
Supplementary Table 1. Regression analysis parameters for GNPs particle size model 
Parameter Value 
ANOVA p-value  
Lack of fit p-value
R2 
0.0001 
0.0790 
0.9639 
Adjusted R2 0.9368 
Predicted R2 0.8678 
Adequate precision 24.848 
Supplementary Table 2. Experimentally determined yield and residual moisture content for 
spray dried gelatin NCMPs 
Run 
Inlet 
temperature 
(°C) 
Aspirator 
rate 
(%) 
Feed 
concentration 
(mg/mL) 
Yield (%) 
Residual 
moisture 
(%) 
1 75 75 4 30.0 ± 5.30 1.32 ± 0.50 
2 100 50 12 42.0 ± 4.75 0.69 ± 0.12 
3 75 100 8 63.0 ± 7.70 1.25 ± 0.35 
4 100 75 8 64.0 ± 2.50 1.01 ± 0.07 
5 100 100 4 55.0 ± 9.40 1.26 ± 0.08 
6 100 100 12 79.0 ± 9.70 1.13 ± 0.43 
7 75 75 12 61.0 ± 6.10 1.07 ± 0.51 
8 100 75 8 66.0 ± 3.50 0.98 ± 0.19 
9 125 100 8 84.5 ± 6.80 0.98 ± 0.28 
10 100 75 8 65.0 ± 2.40 1.03 ± 0.10 
11 100 50 4 35.0 ± 5.50 0.87 ± 0.21 
12 75 50 8 19.0 ± 5.90 0.78 ± 0.14 
13 125 75 4 68.0 ± 1.40 0.95 ± 0.05 
14 125 50 8 53.0 ± 3.20 0.56 ± 0.05 
15 125 75 12 76.0 ±  4.80 0.78 ± 0.07 
Supplementary Table 3. Regression analysis and equation for yield and residual moisture 
responses for spray drying designated model 
Parameter Yield Residual moisture 
ANOVA p-value  
Lack of fit p-value           
R2 
0.0002 
0.0555 
0.9890 
0.0002 
0.2644 
0.9895 
Adjusted R2 0.9692 0.9707 
Predicted R2 0.8296 0.8592 
Adequate precision 22.709 24.459 
Model equation 
Yield=
 = 
+63.73
+13.56 * A
+16.56  * B
+8.75  * C
-3.13  * A * B
-5.75  * A * C
+4.25  * B * C
-7.90  * B2
-4.0 * C2
Moisture content= 
+0.98
-0.14 * A
+0.22   * B
-0.091   * C
-0.013   * A * B
+0.020   * A * C
-0.076   * B2
+0.062   * C2
Where A is inlet temperature, B is aspirator % and C is feed concentration. 
(A) 
(B) 
(C) 
Supplementary Fig. 1. 3D surfaces generated by Box Behnken design representing the effect of 
inlet temperature and aspirator (%) at different feed concentration at (A) 4mg/mL (Upper panels), 
(B) 8 mg/mL (Middle panels) and (C) 12mg/mL (Lower panels) on the yield (%) (Right panels)
and moisture content (Left panels) of spray dried NCMPs. Yield (%) and moisture content decrease
from red to blue color.
